Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME)...
03 mars, 2020
Phase 2 Study Results of OCS-01: An Effective Topical Therapeutic for DME
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME)...
10 février, 2020
Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in DME
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME)...
22 janvier, 2020
Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Trial
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME)...
07 octobre, 2019
Oculis Announces Appointment of Leading Specialists to Scientific Advisory Board
Oculis S.A., a clinicalstage biopharmaceutical company developing next-generation topical ophthalmic treatments ...
17 septembre, 2019
Why a pharma investor quit his day job to follow a vision (Guest interview)
Dr Riad Sherif, CEO of Oculis, emphasises the importance of IP protection to attract investments in developing innovative...
16 mai, 2019
Oculis Expands Portfolio with a Novel Phase II-stage Anti-TNF alpha Antibody Fragment
Lausanne, Switzerland, January 4th, 2019 – Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ...
04 janvier, 2019
Oculis Raises CHF15.5 million in an Extension of its Series B Financing Round
Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments, announces today that it has successfully raised a further CHF15.5...
04 janvier, 2019
Oculis Strengthens its Global Clinical and Business Development Capabilities
Oculis, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments for acute and chronic back- and front-ofthe- eye diseases...
20 novembre, 2018